Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome
- PMID: 36544055
- DOI: 10.1111/apt.17356
Factors associated with lower disease-specific and generic health-related quality of life in Rome IV irritable bowel syndrome
Abstract
Background: Little is known about associations with reduced quality of life in irritable bowel syndrome (IBS) or impact of IBS on quality of life compared with other chronic conditions.
Methods: We collected demographic, gastrointestinal and psychological symptoms, healthcare usage, direct healthcare costs, impact on work and activities of daily living data from 752 individuals with Rome IV-defined IBS. We used the irritable bowel syndrome quality of life (IBS-QOL) and the EQ-5D-5L questionnaires to examine characteristics associated with lower quality of life.
Results: The mean IBS-QOL among all 752 individuals with Rome IV IBS was 48.4 (SD 22.3) and the mean EQ-5D score was 0.570 (SD 0.283), the latter being comparable to people with stroke, leg ulcers or chronic obstructive pulmonary disease. Lower levels of both disease-specific and generic quality of life were associated with severe IBS symptom scores, abnormal anxiety or depression scores, and higher somatoform symptom-reporting and gastrointestinal symptom-specific anxiety scores (p < 0.001 for all analyses). Those with lower quality of life had significantly higher healthcare usage and direct healthcare costs and more impairment in work and activities of daily living (p < 0.01 for all analyses). Avoidance of alcohol, lower educational level, abnormal anxiety, depression or somatoform symptom-reporting scores, and impairment in social leisure activities, home management or maintaining close relationships were all independently associated with lower quality of life.
Conclusion: IBS has a substantial impact on the quality of life of those affected, and worse than observed in some severe chronic organic conditions.
Keywords: EQ-5D; EuroQOL; IBS-QOL; irritable bowel syndrome; quality of life.
© 2022 The Authors. Alimentary Pharmacology & Therapeutics published by John Wiley & Sons Ltd.
Comment in
-
Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here? Authors' reply.Aliment Pharmacol Ther. 2023 Mar;57(6):725-726. doi: 10.1111/apt.17404. Aliment Pharmacol Ther. 2023. PMID: 36821754 No abstract available.
-
Editorial: definition of factors associated with poor quality of life in patients with IBS-but where to from here?Aliment Pharmacol Ther. 2023 Mar;57(6):723-724. doi: 10.1111/apt.17391. Aliment Pharmacol Ther. 2023. PMID: 36821756 No abstract available.
-
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients?Aliment Pharmacol Ther. 2023 May;57(10):1188-1189. doi: 10.1111/apt.17485. Aliment Pharmacol Ther. 2023. PMID: 37094307 No abstract available.
-
Letter: Does irritable bowel syndrome have a greater impact in Western, compared with Asian, patients? Authors' reply.Aliment Pharmacol Ther. 2023 May;57(10):1190-1191. doi: 10.1111/apt.17497. Aliment Pharmacol Ther. 2023. PMID: 37094324 No abstract available.
References
REFERENCES
-
- Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5(10):908-17.
-
- Sperber AD, Bangdiwala SI, Drossman DA, Ghoshal UC, Simren M, Tack J, et al. Worldwide prevalence and burden of functional gastrointestinal disorders, results of Rome foundation global study. Gastroenterology. 2021;160(1):99-114 e3.
-
- Ford AC, Sperber AD, Corsetti M, Camilleri M. Irritable bowel syndrome. Lancet. 2020;396(10263):1675-88.
-
- Holtmann GJ, Ford AC, Talley NJ. Pathophysiology of irritable bowel syndrome. Lancet Gastroenterol Hepatol. 2016;1(2):133-46.
-
- Lacy BE, Pimentel M, Brenner DM, Chey WD, Keefer LA, Long MD, et al. ACG clinical guideline: management of Irritable Bowel Syndrome. Am J Gastroenterol. 2021;116(1):17-44.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources